ISoOR International Society of Organoid Research

Journal of Organoid & Bioscience Volume 4 (2025), page 52-56

Journal of Organoid & Bioscience

Official Journal of ISoOR: www.jobs.isoor.org



Industry News & Perspectives

United Kingdom Launches £75 Million National Roadmap to Phase Out Animal Testing by 2030: A Defining Moment for Human-Relevant Research

ISoOR Insight Team

*E-mail address: info@isoor.org

Abstract

On 11 November 2025, the United Kingdom released its unprecedented "Roadmap for Replacing Animals in Science", announcing a structured transition toward humanrelevant, non-animal scientific methods by 2030. Supported by £75 million in dedicated government funding, the roadmap positions organoids, microphysiological systems (MPS), AI-driven toxicology, and advanced in vitro human models as central components of future regulatory science. This article summarizes key milestones, scientific frameworks, regulatory mechanisms, and sector-wide implications of the UK roadmap. The initiative represents one of the most comprehensive national strategies for animal testing reduction ever implemented by a G7 country, offering a blueprint for global transition toward human-specific research platforms.

Introduction

The United Kingdom has taken a decisive step toward reshaping the scientific and regulatory landscape by announcing a national strategy to accelerate the phase-out of animal testing. Jointly released by the Department for Science, Innovation and Technology (DSIT), DEFRA, and the Home Office on 11 November 2025, the "Roadmap for Replacing Animals in Science" lays out clear goals, timelines, and investments aimed at replacing animal experiments with validated non-animal methodologies (NAMs).

With global momentum building around organoids, organ-on-chip systems, and AIbased predictive methodologies, the UK strategy provides both direction and infrastructure for transitioning these technologies from research environments into regulatory practice. The roadmap fulfills a key Labour Party manifesto pledge and builds on the UK's post-Brexit leadership in animal welfare, including the Animals (Scientific Procedures) Act 1986 and NC3Rs initiatives. It targets a 35% reduction in animal procedures by 2030, from the 2.8 million recorded in Great Britain in 2023.

A Structured Timeline for Phasing Out Animal Testing (2026–2030)

The roadmap outlines measurable and enforceable milestones, using a tiered model to prioritize low-risk tests first. This approach ensures safety while accelerating adoption of NAMs.

Table 2

Year	Milestone	Primary NAMs Involved
2026	Complete elimination of animal testing for skin irritation, skin sensitisation, and serious eye damage/irritation	Reconstructed human epidermis models, corneal organoids, EpiSkin assays
2027	Termination of mouse LD50 assays for botulinum toxin (Botox) potency	Cell-based neuronal organoids, in vitro potency tests
2030	35% reduction in use of dogs and nonhuman primates in pharmacokinetic (PK) and toxicology research	Multi-organ MPS, vascularised organoids, AI-driven PBPK models

Table 2: This timeline represents one of the most detailed national commitments to animal testing reduction on record, with annual progress reports to Parliament.

Scientific Pillars of the UK Roadmap

The strategy rests on three interconnected pillars, with organoids and MPS as foundational tools for human-specific modeling.

1. Human Organoids and Microphysiological Systems (MPS)

Organoids are prioritized for toxicity and safety assessment, disease modeling, drug-response profiling, PK/PD evaluation, and preclinical modeling of biologics and complex modalities. Their ability to mimic human-specific phenotypes—such as zonal liver architecture or intestinal crypt-villus structures—provides distinct advantages over rodent or primate systems, reducing translational failures (estimated at 92% in oncology from preclinical to clinic).

2. AI and Computational Toxicology

AI-driven models will support in silico prediction of compound-target interactions, physiologically based pharmacokinetic (PBPK) modeling, digital toxicology pipelines, and risk assessment based on integrated biological and computational data. For example, machine learning algorithms trained on organoid-derived multiomics datasets could predict hepatotoxicity with >85% accuracy, per NC3Rs pilots.

3. 3D-Bioprinted Human Tissues

Applications include skin irritation testing, hepatotoxicity screening, absorption/penetration studies, and wound healing/reconstructive biology. Bioprinted skin equivalents, validated by EURL ECVAM, have already replaced rabbit Draize tests in cosmetics.

These technologies form an interconnected human-relevant testing ecosystem, with organoids bridging in vitro precision and MPS for systemic interactions.

A £75 Million Investment into National Infrastructure

The funding allocation targets validation, translation, and capacity-building, addressing key barriers like reproducibility and regulatory acceptance.

- **£60 Million: Validation and Translation Centers**
  This supports two major hubs: the Preclinical

Translational Models Hub and the UK Centre for the Validation of Alternative Methods (UKCVAM). Their mandates include NAM validation, inter-laboratory reproducibility initiatives, regulatory interface development, and industry adoption pathways. For instance, UKCVAM will standardize organoid protocols for hepatotoxicity, building on OECD Test Guideline 497.

- **£15.9 Million: National Human In Vitro Disease Model Program**
  Funded by the Medical Research Council (MRC), Innovate UK, and Wellcome Trust, this program supports consortia developing human models for liver disease, neurological disorders, cancer, pain mechanisms, and vascular pathology. Early projects include liver organoid chips for NASH modeling, with £5 million earmarked for biobanking and AI integration.

Governance and Policy Framework

Oversight will be coordinated by a cross-government committee chaired by Lord Patrick Vallance, responsible for publishing national KPIs in 2026, conducting biennial progress reviews, updating regulatory priorities, and streamlining approval pathways for human-relevant methods. The roadmap also includes early-career researcher training (e.g., 500 fellowships in NAMs) and technical workforce development programs, aiming to upskill 2,000 scientists by 2028.

Stakeholder Perspectives

- **NC3Rs:** Praised the roadmap as a "strategically aligned effort that maintains high scientific standards while accelerating innovation," highlighting its integration with the 2023–2028 NC3Rs strategy.
- **UK Pharmaceutical Sector (ABPI):** Highlighted benefits including improved human predictivity, reduced clinical failure rates (potentially 20–30% via organoid screening), and more efficient preclinical workflows.
- **Royal Society of Biology (RSB):** Called the roadmap a model for "ethically aligned scientific progress" and encouraged adoption in other regulatory jurisdictions, noting its alignment with global 3Rs principles.

Industry and academia, including organ-on-chip developers and computational toxicology groups, emphasize that the roadmap provides regulatory clarity, expands validation infrastructure, offers new funding pathways, and creates confidence for industrial investment. However, experts like Dr. Kathy Niakan (stem cell biologist) caution that delivery depends on addressing organoid variability.

Implications for Global Human-Relevant Research

1.Regulatory Transition Toward Human Biology

For the first time, organoids and MPS platforms are being positioned as primary evidence-generation tools, not supplementary methods. This could reduce reliance on the ~2.8 million annual animal procedures in GB (2023 Home Office data).

2.Increased Demand for Standardization

Growth in harmonized SOPs, biobanking best practices, QC/QA frameworks, reference materials, and inter-laboratory reproducibility studies. Challenges include batch variability (e.g., 20–30% in organoid gene expression), addressed via UKCVAM ring trials.

3.Global Competitive Pressure

The UK roadmap is likely to accelerate policy and regulatory responses in the EU (EURL ECVAM's 2024 validation push), US (NIH SOM Center, $87M, September 2025), Japan, Singapore, and South Korea, fostering international consortia.

4.Major Investment Shifts

Expected increases in venture capital (e.g., £100M+ in UK NAM startups by 2027), consortia-based translational programs, industry-academia partnerships, and commercial organoid/MPS platforms. Case study: NC3Rs-funded organoid vaccine testing replaced rabbit pyrogen assays, cutting timelines by 6 months.

Global Outlook

Taken together, these developments signal a broader movement toward human relevant scientific ecosystems, with consequences for clinical translation, drug development success rates, ethical modernization, predictive toxicology, and harmonization of global regulatory frameworks. Compared to the US NIH SOM Center (organoid standardization) or EU REACH revisions (NAM integration), the UK approach uniquely combines funding with enforceable KPIs.

Conclusion

The United Kingdom's Roadmap for Phasing Out Animal Testing by 2030 represents a pivotal moment in modern biomedical research. Combining clear policy directives, targeted financial investment, and scientifically validated alternatives, the roadmap establishes a foundation for human-specific, ethically aligned, and more predictive biological research. Organoids, MPS platforms, AI-driven models, and bioprinted tissues are poised to become central pillars of this new framework–reshaping preclinical research for decades to come. If effectively implemented, the UK roadmap could set a global benchmark for transitioning away from animal-based research systems, potentially reducing failures in oncology and toxicology by 20–30%.

Disclosure Statement

The author declares no competing financial interests related to the content of this Industry News & Perspectives article.

Funding Statement

No external funding was received for the preparation of this article.

References

[1] NC3Rs Strategy National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs). The NC3Rs strategy 2022-2024. NC3Rs, July 2022. Available at: https://nc3rs.org.uk/sites/default/files/2022-07/The%20NC3Rs%20strategy%202022%20to%202024.pdf NC3Rs

[2] UK Government Strategy (instead of "UKRI project" mis- reference) *Department for Science, Innovation & Technology; Home Office; Department for Environment, Food & Rural Affairs. Replacing animals in science: A strategy to support the development, validation and uptake of alternative methods.* UK Government, 11 November 2025. CP 1429. ISBN 978- 1- 5286- 5871- 3. Available at: *https://www.gov.uk/government/publications/replacing-animals-in-science-strategy GOV.UK+1*

[3] ABPI Comment Association of the British Pharmaceutical Industry (ABPI). Quoted in: Animal testing to be phased out faster as UK unveils roadmap for alternative methods. UK Government press release, 11 November 2025. Available at: https://www.gov.uk/government/news/animal-testing-to-be-phased-out-faster-as-uk-unveils-roadmap-for-alternative-methods GOV.UK

[4] Royal Society of Biology (RSB) Response Royal Society of Biology. "RSB response to Government's roadmap for replacing animals in science." Quoted in UK Government press release, 11 November 2025. Available at: https://www.gov.uk/government/news/animal-testing-to-be-phased-out-faster-as-uk-unveils-roadmap-for-alternative-methods